ArticleFuture oncology (London, England)2025

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.

François Cherifi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.